bioMONTR Labs to Provide Testing Services for CytoDyn PRO 140 Clinical Trials

Research Triangle Park, NC, October 13, 2016 (Newswire.com) - bioMONTR Labs announced today they have entered into new Master Service Agreements to provide HIV-1 viral load testing services for CytoDyn’s ongoing Phase 2b PRO 140 Monotherapy Extension Study and their upcoming Phase 3 PRO 140 Monotherapy Study.

bioMONTR Labs, a CLIA Certified lab located in Research Triangle Park, NC since 2010 offers a comprehensive menu of high-complexity, molecular assays as well other proprietary and esoteric molecular testing. Anita M. McClernon, Vice President and Director of Laboratory Services for bioMONTR Labs stated that “bioMONTR Labs is uniquely positioned to support ongoing and new clinical trials by providing access to our highly specialized, proprietary methods and expertise developed over the last 30 years. Our support provides companies with the ability to focus on developing new and better therapies for those living with HIV.”

"We are excited to provide our proprietary HIV-1 SuperLow single copy assay to assess the efficacy for this groundbreaking new HIV therapy ."

Daniel McClernon, President & Chief Scientific Officer

Financial terms were not disclosed. 

Source: bioMONTR Labs